Skip to main content
. 2016 Sep 8;7(49):81906–81917. doi: 10.18632/oncotarget.11918

Figure 5. Comparison of the actuarial risk for developing BM between serum CEA ≥ 23 ng/mL and serum CEA < 23 ng/mL.

Figure 5